News has moved

We have now moved the news back to the website.

http://www.hivhaven.com/

NY-Presbyterian/Columbia reports laparoscopic living donor liver retrieval for adults

A team of surgeons at NewYork-Presbyterian/Columbia University Medical Center is the first in the country to report a fully laparoscopic hepatectomy - the removal of a portion of the liver - from a living adult donor for adult and teenage recipients. The procedure advances transplant surgery and offers hope for addressing the significant shortage of liver donors.

Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people

People co-infected with HIV and HCV, mostly with hepatitis C virus (HCV) genotype 3, responded about as well as HIV-negative people to interferon-based therapy after taking into account other factors associated with poor treatment response, according to an Italian study presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this month in Denver. Advanced liver fibrosis was common in the co-infected group, supporting the need for early treatment.

Hepatitis C screening should be expanded in Canada, study says

Incidents of the disease, a major cause of cirrhosis of the liver, remain underdiagnosed, undertreated say medical experts.

Karen Robson says it is only because of her family physician’s thoroughness that she found out she had Hepatitis C.

Achillion stock plunges as FDA maintains clinical hold on hep C drug

Achillion Pharmaceuticals Inc <ACHN.O> said the U.S. Food and Drug Administration decided not to lift a clinical hold it had placed on the firm's hepatitis C drug, sovaprevir, leaving an uncertain fate for the company's most promising drug.

The news caused Achillion's shares to plunge 45 percent in after-market trade on Friday.